In this article, we will discuss Olaparib (Drug Interaction-1). So, let’s get started.
Use with Anticancer Agents
Clinical studies of Olaparib with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.